A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

NCT06611033 | Completed Phase 1 FDA Drug

• 1 other identifier: V118C-001
• Study Type: interventional
• Target: 65
• Locations: 1 country
• Sites: 3

Brief Summary

The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.

Conditions

Healthy

Outcome Measures

Primary Outcomes (7)

• Number of Participants with Solicited Injection Site Adverse Events (AEs)

  An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants with a solicited injection-site AE will be reported.

  Up to approximately 7 days after each vaccination

• Number of Participants with Solicited Systemic AEs

  An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants with a solicited systemic AE will be reported.

  Up to approximately 7 days after each vaccination

• Number of Participants with Immediate AEs Following Vaccination

  An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants with Immediate AEs following vaccination will be reported.

  Up to approximately 30 minutes after each vaccination

• Number of Participants with Unsolicited AEs

  An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An unsolicited AE is an AE that is not solicited using a vaccine report card (VRC) and that is communicated by a participant. The number of participants that experienced an unsolicited AE will be reported.

  Up to approximately 28 days after each vaccination

• Number of Participants With a Serious Adverse Event (SAE)

  An SAE is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. The number of participants who experience an SAE will be reported.

  Up to approximately 12 months after final vaccination

• Number of Participants with a Medically Attended Adverse Event (MAAE)

  An MAAE is defined as an adverse event in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason. The number of participants who experience an MAAE will be reported.

  Up to approximately 12 months after final vaccination

• Number of Participants with an Event of Clinical Interest (ECI)

  An ECI includes but is not limited to: 1) An overdose defined as: A participant receiving more than 1 dose of study vaccine in a 24-hour period or more than 2 doses of study vaccine throughout the study. 2) Potential drug-induced liver injury (DILI) events defined as: An elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) lab value that is ≥3 times the upper limit of normal (ULN) and an elevated total bilirubin lab value that is ≥2 times ULN and, at the same time, an alkaline phosphatase lab value that is \<2 times ULN, as determined by way of protocol-specified laboratory testing or unscheduled laboratory testing. 3) Potential immune-mediated disease (pIMDs) defined as: A subset of AEs that include either an established autoimmune disease(s) or Inflammatory and/or neurologic disorder(s), which might or might not have an autoimmune etiology. The number of participants who experience an ECI will be reported.

  Up to approximately 12 months after final vaccination

Secondary Outcomes (1)

• Serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs)

  Day 28 postvaccination

Study Arms (3)

V118C

EXPERIMENTAL

Participants receive intramuscular (IM) injection of V118C in a 2-dose regimen administered on Day 1 and Day 29.

Biological: V118C

V118

EXPERIMENTAL

Participants receive IM injection of V118 in a 2-dose regimen administered on Day 1 and Day 29.

Biological: V118; Biological: Saline

PREVNAR 20™ + Saline

ACTIVE COMPARATOR

Participants receive one dose of IM injection of PREVNAR 20™ in a 2-dose regimen on Day 1 followed by one dose of saline on Day 29.

Biological: PREVNAR 20™; Biological: Saline

Interventions

V118C BIOLOGICAL

Intramuscular Administration

V118C

V118 BIOLOGICAL

Intramuscular Administration

V118

PREVNAR 20™ BIOLOGICAL

Intramuscular Administration

PREVNAR 20™ + Saline

Saline BIOLOGICAL

Intramuscular Administration

PREVNAR 20™ + Saline; V118

Eligibility Criteria

• Age: 18 Years - 49 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Is in good health before randomization

You may not qualify if:

• Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination.
• Has a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Study Sites (3)

Velocity Clinical Research, Hallandale Beach ( Site 0003)

Hallandale, Florida, 33009, United States

Location

Research Centers of America ( Hollywood ) ( Site 0002)

Hollywood, Florida, 33024, United States

Location

University of Texas Medical Branch ( Site 0001)

Galveston, Texas, 77555-1115, United States

Location

Related Links

• Merck Clinical Trials Information

MeSH Terms

Interventions

Sodium Chloride

Intervention Hierarchy (Ancestors)

Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 20, 2024
• First Posted: September 24, 2024
• Study Start: September 25, 2024
• Primary Completion: January 9, 2026
• Study Completion: January 9, 2026
• Last Updated: January 20, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will share

Locations

US (3)